{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:00:19Z","timestamp":1767650419391,"version":"build-2065373602"},"reference-count":100,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zoonoses Anticipation and Preparedness Initiative","award":["IMI Grant Agreement no. 115760"],"award-info":[{"award-number":["IMI Grant Agreement no. 115760"]}]},{"name":"European Union\u2019s Horizon 2020","award":["Grant Agreement Nos. 733176 (RABYD-VAX consortium)"],"award-info":[{"award-number":["Grant Agreement Nos. 733176 (RABYD-VAX consortium)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The tremendous global impact of the current SARS-CoV-2 pandemic, as well as other current and recent outbreaks of (re)emerging viruses, emphasize the need for fast-track development of effective vaccines. Yellow fever virus 17D (YF17D) is a live-attenuated virus vaccine with an impressive efficacy record in humans, and therefore, it is a very attractive platform for the development of novel chimeric vaccines against various pathogens. In the present study, we generated a YF17D-based replicon vaccine platform by replacing the prM and E surface proteins of YF17D with antigenic subdomains from the spike (S) proteins of three different betacoronaviruses: MERS-CoV, SARS-CoV and MHV. The prM and E proteins were provided in trans for the packaging of these RNA replicons into single-round infectious particles capable of expressing coronavirus antigens in infected cells. YF17D replicon particles expressing the S1 regions of the MERS-CoV and SARS-CoV spike proteins were immunogenic in mice and elicited (neutralizing) antibody responses against both the YF17D vector and the coronavirus inserts. Thus, YF17D replicon-based vaccines, and their potential DNA- or mRNA-based derivatives, may constitute a promising and particularly safe vaccine platform for current and future emerging coronaviruses.<\/jats:p>","DOI":"10.3390\/vaccines9121492","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T21:32:40Z","timestamp":1639690360000},"page":"1492","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8830-7055","authenticated-orcid":false,"given":"Nadia","family":"Oreshkova","sequence":"first","affiliation":[{"name":"Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5813-0065","authenticated-orcid":false,"given":"Sebenzile K.","family":"Myeni","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niraj","family":"Mishra","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Herestraat 49 Box 1043, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina C.","family":"Albulescu","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim J.","family":"Dalebout","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3297-2309","authenticated-orcid":false,"given":"Eric J.","family":"Snijder","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Bredenbeek","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-9166","authenticated-orcid":false,"given":"Kai","family":"Dallmeier","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Herestraat 49 Box 1043, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5779-7386","authenticated-orcid":false,"given":"Marjolein","family":"Kikkert","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases LU-CID, Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_2","unstructured":"(2021, December 15). RAPS. Available online: https:\/\/www.raps.org\/news-and-articles\/news-articles\/2020\/3\/covid-19-vaccine-tracker."},{"key":"ref_3","unstructured":"Knipe, D.M. (2013). Flaviviridae. Fields Virology, Lippincott Willims & Wilkins. [6th ed.]."},{"key":"ref_4","unstructured":"WHO (2021, December 15). Yellow Fever. 7 May 2019. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/yellow-fever."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1084\/jem.65.6.767","article-title":"The Effect Of Prolonged Cultivation In Vitro Upon The Pathogenicity Of Yellow Fever Virus","volume":"65","author":"Theiler","year":"1937","journal-title":"J. Exp. Med."},{"key":"ref_6","unstructured":"WHO (2021, December 15). SAGE Working Group: Background Paper on Yellow Fever Vaccine. Available online: https:\/\/www.who.int\/immunization\/sage\/meetings\/2013\/april\/1_Background_Paper_Yellow_Fever_Vaccines.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wieten, R.W., Jonker, E.F., van Leeuwen, E.M., Remmerswaal, E.B., Ten Berge, I.J., de Visser, A.W., van Genderen, P.J., Goorhuis, A., Visser, L.G., and Grobusch, M.P. (2016). A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149871"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmaid.2016.12.003","article-title":"Yellow fever vaccination\u2014Once in a lifetime?","volume":"15","author":"Grobusch","year":"2017","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.4161\/hv.28117","article-title":"The yellow fever 17D virus as a platform for new live attenuated vaccines","volume":"10","author":"Bonaldo","year":"2014","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9197","DOI":"10.1128\/JVI.74.19.9197-9205.2000","article-title":"Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases","volume":"74","author":"McAllister","year":"2000","journal-title":"J. Virol"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.20041526","article-title":"Yellow fever 17D as a vaccine vector for microbial CTL epitopes: Protection in a rodent malaria model","volume":"201","author":"Tao","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1084\/jem.20051352","article-title":"Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes","volume":"202","author":"Longman","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1743-422X-8-127","article-title":"Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome","volume":"8","author":"Nogueira","year":"2011","journal-title":"Virol. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1385\/CBB:44:3:313","article-title":"Expression of foreign protein epitopes at the surface of recombinant yellow fever 17D viruses based on three-dimensional modeling of its envelope protein","volume":"44","author":"Bonaldo","year":"2006","journal-title":"Cell Biochem. Biophys."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8602","DOI":"10.1128\/JVI.79.13.8602-8613.2005","article-title":"Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface","volume":"79","author":"Bonaldo","year":"2005","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2009.10.033","article-title":"Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus","volume":"396","author":"Rumyantsev","year":"2010","journal-title":"Virology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","article-title":"A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins","volume":"345","author":"Bredenbeek","year":"2006","journal-title":"Virology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1743-422X-4-115","article-title":"Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes","volume":"4","author":"Bonaldo","year":"2007","journal-title":"Virol. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1128\/JVI.02255-09","article-title":"Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques","volume":"84","author":"Bonaldo","year":"2010","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1016\/j.vaccine.2010.06.052","article-title":"Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development","volume":"28","author":"Franco","year":"2010","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.vaccine.2010.11.079","article-title":"Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs","volume":"29","author":"Jiang","year":"2011","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nogueira, R.T., Nogueira, A.R., Pereira, M.C., Rodrigues, M.M., Neves, P.C., Galler, R., and Bonaldo, M.C. (2013). Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi. PLoS ONE, 8.","DOI":"10.1371\/annotation\/39b41d98-b117-41cf-b5de-b8486a67b1cd"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Martins, M.A., Bonaldo, M.C., Rudersdorf, R.A., Piaskowski, S.M., Rakasz, E.G., Weisgrau, K.L., Furlott, J.R., Eernisse, C.M., Veloso de Santana, M.G., and Hidalgo, B. (2013). Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054434"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","article-title":"A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate","volume":"590","author":"Vercruysse","year":"2021","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1128\/JVI.73.4.3095-3101.1999","article-title":"Yellow fever\/Japanese encephalitis chimeric viruses: Construction and biological properties","volume":"73","author":"Chambers","year":"1999","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1128\/JVI.74.12.5477-5485.2000","article-title":"Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates","volume":"74","author":"Guirakhoo","year":"2000","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/viro.1999.9695","article-title":"Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis","volume":"257","author":"Guirakhoo","year":"1999","journal-title":"Virology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41541-018-0092-2","article-title":"A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice","volume":"3","author":"Kum","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","article-title":"The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: Systematic review","volume":"86","author":"Thomas","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2009.05.018","article-title":"Yellow fever vaccine\u2014How does it work and why do rare cases of serious adverse events take place?","volume":"21","author":"Barrett","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1099\/jgv.0.000026","article-title":"Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone","volume":"96","author":"Jiang","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.virol.2006.02.036","article-title":"Evaluation of replicative capacity and genetic stability of West Nile virus replicons using highly efficient packaging cell lines","volume":"351","author":"Fayzulin","year":"2006","journal-title":"Virology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.virol.2006.04.003","article-title":"Production and characterization of vaccines based on flaviviruses defective in replication","volume":"351","author":"Mason","year":"2006","journal-title":"Virology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1080\/21645515.2017.1373920","article-title":"Application of replication-defective West Nile virus vector to non-flavivirus vaccine targets","volume":"13","author":"Vaine","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_37","unstructured":"Hilgenfeld, R., and Vasudevan, S.G. (2018). Establishment and Application of Flavivirus Replicons. Dengue and Zika: Control and Antiviral Treatment Strategies, Springer Singapore."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12929-015-0181-8","article-title":"Japanese encephalitis virus replicon-based vaccine expressing enterovirus-71 epitope confers dual protection from lethal challenges","volume":"22","author":"Huang","year":"2015","journal-title":"J. Biomed. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S1060","DOI":"10.1093\/infdis\/jir347","article-title":"Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection","volume":"204","author":"Reynard","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1093\/infdis\/jiv019","article-title":"A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates","volume":"212","author":"Pyankov","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1128\/JVI.77.3.2265-2270.2003","article-title":"Fine mapping of a cis-acting sequence element in yellow fever virus RNA that is required for RNA replication and cyclization","volume":"77","author":"Corver","year":"2003","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1128\/jvi.71.2.1497-1505.1997","article-title":"Subgenomic replicons of the flavivirus Kunjin: Construction and applications","volume":"71","author":"Khromykh","year":"1997","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Schindewolf, C., and Menachery, V.D. (2019). Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism. Viruses, 11.","DOI":"10.3390\/v11010074"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Abdulla, Z.A., Al-Bashir, S.M., Al-Salih, N.S., Aldamen, A.A., and Abdulazeez, M.Z. (2021). A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development. Pathogens, 10.","DOI":"10.3390\/pathogens10070788"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Xia, X. (2021). Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design. Viruses, 13.","DOI":"10.3390\/v13010109"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1099\/vir.0.18860-0","article-title":"A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication","volume":"84","author":"Bredenbeek","year":"2003","journal-title":"J. Gen. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41426-018-0161-7","article-title":"Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone","volume":"7","author":"Touret","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_48","first-page":"227","article-title":"The Method Of \u2018Right And Wrong Cases\u2019 (\u2018Constant Stimuli\u2019) Without Gauss\u2019s Formulae","volume":"2","author":"Spearman","year":"1908","journal-title":"Br. J. Psychol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche","volume":"162","year":"1931","journal-title":"Naunyn-Schmiedebergs Arch. F\u00fcr Exp. Pathol. Und Pharmakol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e02494-19","DOI":"10.1128\/mBio.02494-19","article-title":"A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies","volume":"11","author":"Mishra","year":"2020","journal-title":"mBio"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"12591","DOI":"10.1128\/JVI.78.22.12591-12602.2004","article-title":"The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals","volume":"78","author":"Rouille","year":"2004","journal-title":"J. Virol.."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses: Gene expression, replication, and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9379","DOI":"10.1128\/JVI.01277-13","article-title":"The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies","volume":"87","author":"Mou","year":"2013","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12127","DOI":"10.1016\/S0021-9258(18)98867-8","article-title":"Arg-X-Lys\/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway","volume":"266","author":"Hosaka","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_57","unstructured":"(2020, January 03). Available online. Available online: https:\/\/services.healthtech.dtu.dk\/service.php?NetNGlyc-1.0."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1016\/j.vaccine.2012.03.003","article-title":"A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain","volume":"30","author":"Thibodeaux","year":"2012","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Meier, K.C., Gardner, C.L., Khoretonenko, M.V., Klimstra, W.B., and Ryman, K.D. (2009). A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000614"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1080\/22221751.2019.1694394","article-title":"Limited evolution of the yellow fever virus 17d in a mouse infection model","volume":"8","author":"Kum","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/22221751.2020.1730709","article-title":"A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice","volume":"9","author":"Kum","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Teo, S.P. (2021). Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. J. Pharm. Pract., 8971900211009650.","DOI":"10.1177\/08971900211009650"},{"key":"ref_63","unstructured":"EMA (2021, December 15). AstraZeneca\u2019s COVID-19 Vaccine: Benefits and Risks in Context. Available online: https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-benefits-risks-context."},{"key":"ref_64","unstructured":"EMA (2021, December 15). COVID-19 Vaccine Janssen. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/covid-19-vaccine-janssen."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejim.2021.05.031","article-title":"Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines","volume":"89","author":"Cattaneo","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajem.2021.05.054","article-title":"Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines","volume":"49","author":"Long","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jamacardio.2021.2821","article-title":"Myocarditis Occurring after Immunization with mRNA-Based COVID-19 Vaccines","volume":"6","author":"Shay","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1084\/jem.20051720","article-title":"Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity","volume":"203","author":"Querec","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1084\/jem.20082292","article-title":"Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses","volume":"205","author":"Gaucher","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri2629","article-title":"Learning immunology from the yellow fever vaccine: Innate immunity to systems vaccinology","volume":"9","author":"Pulendran","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J. Clin. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cyto.2008.02.007","article-title":"Detection of Th1\/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay","volume":"42","author":"Santos","year":"2008","journal-title":"Cytokine"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Watson, A.M., and Klimstra, W.B. (2017). T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models. Viruses, 9.","DOI":"10.3390\/v9040077"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","article-title":"The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response","volume":"183","author":"Akondy","year":"2009","journal-title":"J. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/14760584.2013.836320","article-title":"Safety profile of the yellow fever vaccine Stamaril(R): A 17-year review","volume":"12","author":"Cottin","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"taw045","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007\u20132013","volume":"23","author":"Lindsey","year":"2016","journal-title":"J. Travel Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"ref_79","unstructured":"(2021, December 15). WHO. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/329432\/WHO-WHE-IHM-2019.11-eng.pdf?ua=1."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.vaccine.2021.02.033","article-title":"Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models","volume":"39","author":"Raynal","year":"2021","journal-title":"Vaccine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: A double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/mic.0.049601-0","article-title":"Pre-existing immunity against vaccine vectors\u2014Friend or foe?","volume":"159","author":"Saxena","year":"2013","journal-title":"Microbiology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/CVI.00031-12","article-title":"Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity","volume":"19","author":"Uematsu","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/infdis\/161.6.1134","article-title":"Immunogenicity of a purified fragment of 17D yellow fever envelope protein","volume":"161","author":"Brandriss","year":"1990","journal-title":"J. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/0042-6822(87)90141-3","article-title":"Location of a neutralization determinant in the E protein of yellow fever virus (17D vaccine strain)","volume":"161","author":"Lobigs","year":"1987","journal-title":"Virology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.virusres.2007.01.021","article-title":"Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease","volume":"133","author":"Enjuanes","year":"2008","journal-title":"Virus Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.coviro.2017.03.007","article-title":"Middle East respiratory syndrome coronavirus vaccines: Current status and novel approaches","volume":"23","author":"Okba","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1016\/j.cell.2021.05.040","article-title":"Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques","volume":"184","author":"He","year":"2021","journal-title":"Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1099\/vir.0.000075","article-title":"Spectrum of disease outcomes in mice infected with YFV-17D","volume":"96","author":"Erickson","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.4049\/jimmunol.1402605","article-title":"CD8+ T cells complement antibodies in protecting against yellow fever virus","volume":"194","author":"Bassi","year":"2015","journal-title":"J. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/viro.2002.1432","article-title":"Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice","volume":"296","author":"Harrington","year":"2002","journal-title":"Virology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1016\/j.vaccine.2014.07.051","article-title":"Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen","volume":"32","author":"Oreshkova","year":"2014","journal-title":"Vaccine"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Seo, Y.B., Suh, Y.S., Ryu, J.I., Jang, H., Oh, H., Koo, B.S., Seo, S.H., Hong, J.J., Song, M., and Kim, S.J. (2021). Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates. Vaccines, 9.","DOI":"10.3390\/vaccines9040307"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.omtm.2021.06.003","article-title":"Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice","volume":"22","author":"Freyn","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Tu, Y., Hu, Y., Fan, G., Chen, Z., Liu, L., Man, D., Liu, S., Tang, C., Zhang, Y., and Dai, W. (2014). Protective effects of membrane-anchored and secreted DNA vaccines encoding fatty acid-binding protein and glutathione S-transferase against Schistosoma japonicum. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086575"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Cornelissen, L.A., de Leeuw, O.S., Tacken, M.G., Klos, H.C., de Vries, R.P., de Boer-Luijtze, E.A., van Zoelen-Bos, D.J., Rigter, A., Rottier, P.J., and Moormann, R.J. (2012). Protective efficacy of Newcastle disease virus expressing soluble trimeric hemagglutinin against highly pathogenic H5N1 influenza in chickens and mice. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044447"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Roberts, A., Deming, D., Paddock, C.D., Cheng, A., Yount, B., Vogel, L., Herman, B.D., Sheahan, T., Heise, M., and Genrich, G.L. (2007). A mouse-adapted SARS-coronavirus causes disease and mortality in BALB\/c mice. PLoS Pathog., 3.","DOI":"10.1371\/journal.ppat.0030005"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat. Rev. Microbiol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/12\/1492\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:50:04Z","timestamp":1760169004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/12\/1492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":100,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["vaccines9121492"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9121492","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2021,12,16]]}}}